Cargando…
Combining Immunotherapy with Transarterial Radioembolization
Hepatocellular carcinoma (HCC) has a high mortality rate due to the diagnosis of patients at advanced stages and ineffective systemic therapies. Immunotherapy is considered a new treatment option for unresectable HCC alternatives to the limitations of conventional cytotoxic chemotherapy. In this cas...
Autores principales: | Balaban Genc, Zeynep Ceren, Soydemır, Efe, Ersoy, Seval Ay, Ones, Tunc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10348490/ https://www.ncbi.nlm.nih.gov/pubmed/37456187 http://dx.doi.org/10.4103/ijnm.ijnm_180_22 |
Ejemplares similares
-
Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium
por: Girardet, Raphaël, et al.
Publicado: (2020) -
Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports
por: Carvalho, Vithor de Oliveira, et al.
Publicado: (2020) -
Effect of Anticoagulants in Pulmonary Thromboembolism in Post-COVID-19 Patients
por: Çınar, Caner, et al.
Publicado: (2023) -
Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report
por: Ljuboja, Damir, et al.
Publicado: (2020) -
Long-term survival with transarterial chemoembolization and radioembolization in a patient with cancers of unknown primary
por: Aktas, Gokmen, et al.
Publicado: (2018)